Literature DB >> 34526679

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.

Karina Huynh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34526679     DOI: 10.1038/s41569-021-00627-z

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

2.  Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Authors:  Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker
Journal:  Circulation       Date:  2021-08-29       Impact factor: 29.690

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.